Načítá se...
The DKA that wasn't: a case of euglycemic diabetic ketoacidosis due to empagliflozin
Sodium glucose co-transporter (SGLT-2) inhibitor is a relatively new medication used to treat diabetes. At present, the Food and Drug Administration (FDA) has only approved three medications (canagliflozin, dapagliflozin and empagliflozin) in this drug class for the management of Type 2 diabetes. In...
Uloženo v:
| Vydáno v: | Oxf Med Case Reports |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Oxford University Press
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4962888/ https://ncbi.nlm.nih.gov/pubmed/27471597 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/omcr/omw061 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|